Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-Week analysis

AIDS

Volumn 23, Issue 13, 2009, Pages 1679-1688

  Mills, Anthony M ^a   Nelson, Mark ^b   Jayaweera, Dushyantha ^c   Ruxrungtham, Kiat ^d,e   Cassetti, Isabel ^e   Girard, Pierre Marie ^f   Workman, Cassy ^g   Dierynck, Inge ^h   Sekar, Vanitha ^a   Abeele, Carline Vanden ^h   Lavreys, Ludo ^h  

^a Chelsea and Westminster Hospital ^*  (United States)

^b CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^c THAI RED CROSS AIDS RESEARCH CENTRE   (Thailand)

^d CHULALONGKORN UNIVERSITY   (Thailand)

^e Helios Salud ^*  (Argentina)

^f AIDS Research Initiative   (Australia)

^g TIBOTEC BVBA   (Belgium)

^h Tibotec Inc   (United States)

Author keywords

Antiretroviral therapy; Clinical trials; Darunavir; HIV; Lopinavir; Protease inhibitors

Indexed keywords

DARUNAVIR; EMTRICITABINE; LOPINAVIR; RITONAVIR; TENOFOVIR;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CD4 LYMPHOCYTE COUNT; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; HEPATITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; VIRUS LOAD;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, MULTIPLE, VIRAL; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; MIDDLE AGED; PYRIMIDINONES; RITONAVIR; RNA, VIRAL; SULFONAMIDES; TREATMENT OUTCOME; VIRAL LOAD;

EID: 69449092725     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32832d7350     Document Type: Article

References (37)

1. Clotet B, Bellos N, Molina J-M, Cooper D, Goffard J-C, Lazzarin A, et al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet 2007; 369:1169-1178. (Pubitemid 46541620)
2. Molina JM, Cohen C, Katlama C, Grinsztejn B, Timerman A, Pedro RD, et al. Safety and efficacy of darunavir (TMC114) with low-dose ritonavir in treatment-experienced patients: 24-week results of POWER 3. J Acquir Immune Defic Syndr 2007; 46:24-31. (Pubitemid 47514614)
3. Madruga JV, Berger D, McMurchie M, Suter F, Banhegyi D, Ruxrungtham K, et al. Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced HIV-infected patients in TITAN: a randomised controlled phase III trial. Lancet 2007; 370:49-58. (Pubitemid 47023100)
4. Bánhegyi D, Katlama C, Da Cunha C, Schneider S, Rachlis A, Romanenko O, et al. Phase III TITAN week 96 final analysis: efficacy/safety of darunavir/ritonavir (DRV/r) vs lopinavir/ritonavir (LPV/r) in LPV/r- naïve, treatment-experienced patients [abstract P22]. 9th International Congress on HIV and Drug Therapy in HIV Infection. Glasgow, UK; 9-13 November 2008.
5. Back D, Sekar V, Hoetelmans RMW. Darunavir: pharmacokinetics and drug interactions. Antivir Ther 2008; 13:1-13.
6. Boffito M, Miralles D, Hill A. Pharmacokinetics, efficacy, and safety of darunavir/ritonavir 800/100mg once-daily in treatment-naïve and -experienced patients. HIV Clin Trials 2008; 9:418-427.
7. De Meyer S, Azijn H, Surleraux D, Jochmans D, Tahri A, Pauwels R, et al. TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates. Antimicrob Agents Chemother 2005; 49:2314-2321. (Pubitemid 40734460)
8. Maggiolo F, Ravasio L, Ripamonti D, Gregis G, Quinzan G, Arici C, et al. Similar adherence rates favor different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitors. Clin Infect Dis 2005; 40:158-163. (Pubitemid 40053474)
9. De Meyer SM, Spinosa-Guzman S, Vangeneugden TJ, de Béthune MP, Miralles GD. Efficacy of once-daily darunavir/ritonavir 800/100mg in HIV-infected, treatment-experienced patients with no baseline resistance-associated mutations to darunavir. J AIDS 2008; 49:179-182.
10. Ortiz R, Dejesus E, Khanlou H, Voronin E, van Lunzen J, Andrade-Villanueva J, et al. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naïve HIV-1-infected patients at week 48. AIDS 2008; 22:1389-1397.
11. DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. 3 November 2008. http://www.aidsinfo.nih.gov/Guidelines/ GuidelineDetail.aspx?GuidelineID=7. [Accessed 13 January 2009].
12. Hammer SM, Eron JJ Jr, Reiss P, Schooley RT, Thompson MA, Walmsley S, et al., International AIDS Society-USA. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 2008; 300:555-570.
13. Walsh JC, Mandalia S, Gazzard BG. Responses to a 1 month self-report on adherence to antiretroviral therapy are consistent with electronic data and virological treatment outcome. AIDS 2002; 16:269-277. (Pubitemid 34118574)
14. Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000; 133:21-30. (Pubitemid 30432540)
15. Mills AM, Chetchotisakd P, DeMasi R, Chen L, Lefebvre E, Smets E, et al. Adherence to darunavir/ritonavir and lopinavir/ritonavir in treatment-naïve HIV patients in ARTEMIS [abstract 61]. Frontiers in Drug Development for Antiretroviral Therapies. Rio Grande, Puerto Rico; 9-12 December 2008.
16. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. NIH Publication No. 02-5215. September 2002. http://www.nhlbi.nih.gov/ guidelines/cholesterol/atp3-rpt.htm. [Accessed 13 January 2009].
17. Perno CF, Moyle G, Tsoukas C, Ratanasuwan W, Gatell J, Schechter M. Overcoming resistance to existing therapies in HIV-infected patients: the role of new antiretroviral drugs. J Med Virol 2008; 80:565-576. (Pubitemid 351358551)
18. Chen R, Quinones-Mateu ME, Mansky LM. Drug resistance, virus fitness and HIV-1 mutagenesis. Curr Pharm Des 2004; 10:4065-4070. (Pubitemid 39654468)
19. Murray JS, Elashoff MR, Iacono-Connors LC, Cvetkovich TA, Struble KA. The use of plasma HIV RNA as a study endpoint in efficacy trials of antiretroviral drugs. AIDS 1999; 13:797-804.
20. O'Brien WA, Hartigan PM, Martin D, Esinhart J, Hill A, Benoit S, et al. Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS. N Engl J Med 1996; 334:426-431.
21. Molina JM, Podsadecki TJ, Johnson MA, Wilkin A, Domingo P, Myers R, et al. A lopinavir/ritonavir-based once-daily regimen results in better compliance and is noninferior to a twice-daily regimen through 96 weeks. AIDS Res Hum Retroviruses 2007; 23:1505-1514.
22. Smith K, Fine D, Patel P, Bellos N, Sloan L, Lackey P, et al. Efficacy and safety of abacavir/lamivudine compared to tenofovir/emtricitabine in combination with once-daily lopinavir/ritonavir through 48 weeks in the HEAT Study [abstract 774]. 15th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA; 3-6 February 2008.
23. Gathe J, da Silva B, Loufty M, Podzamczer D, Rubio R, Gibbs S, et al. Study M05-730 primary efficacy results at week 48: phase 3, randomized, open-label study of lopinavir/ritonavir tablets once daily vs twice daily, co-administered with tenofovir DF R emtricitabine in antiretroviral-naïve HIV-1-infected subjects [abstract 775]. 15th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA; 3-6 February 2008.
24. Egger M, May M, Chêne G, Phillips AN, Ledergerber B, Dabis F, et al., ART Cohort Collaboration. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002; 360:119-129.
25. Krentz HB, Auld MC, Gill MJ. The high cost of medical care for patients who present late (CD4 <200 cells/ml) with HIV infection. HIV Med 2004; 5:93-98.
26. Sabin CA, Smith CJ, Gumley H, Murphy G, Lampe FC, Phillips AN, et al. Late presenters in the era of highly active antiretroviral therapy: uptake of and responses to antiretroviral therapy. AIDS 2004; 18:2145-2151. (Pubitemid 39463679)
27. Klein D, Hurley LB, Merrill D, Quesenberry CP Jr, Consortium for HIV/AIDS Interregional Research. Review of medical encounters in the 5 years before a diagnosis of HIV-1 infection: implications for early detection. J Acquir Immune Defic Syndr 2003; 32:143-152.
28. Schwarcz S, Hsu L, Dilley JW, Loeb L, Nelson K, Boyd S. Late diagnosis of HIV infection trends, prevalence, and characteristics of personswhoseHIVdiagnosis occurred within 12months of developing AIDS. J AcquirImmune Defic Syndr 2006; 43:491-494. (Pubitemid 44737109)
29. Coker R. Testing times: unmet need in testing, treatment and care for HIV/AIDS in Europe. HIV in Europe 2007. Brussels, Belgium; 25-27 November 2007. http://www.hiveurope2007.eu/resources.html. [Accessed 13 January 2009].
30. Molina J, Andrade-Villanueva J, Echevarria J, Absalon J, McGrath D, Yang R, et al. Atazanavir-ritonavir vs lopinavirritonavir in antiretroviral- naïve HIV-1 infected patients:CASTLE 96 week efficacy and safety [abstract H-1250d]. 48th International Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, USA; 25-28 October 2008.
31. Walmsley S, Avihingsanon A, Slim J, Ward D, Ruxrungtham K, Bruntetta J, et al. Gemini: a noninferiority study of saquinavir/ritonavir versus lopinavir/ritonavir as initial HIV-1 therapy in adults. J AIDS 2009; 50:367-374.
32. Kempf DJ, King MS, Bernstein B, Cernohous P, Bauer E, Moseley J, et al. Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine. J Infect Dis 2004; 189:51-60. (Pubitemid 38122329)
33. Zazzi M. Lack of major resistance mutations in HIV-1 protease at failure of boosted protease inhibitor-based first-line antiretroviral treatment. Rev Antivir Ther 2007; 2:4-12.
34. Katlama C, Esposito R, Gatell JM, Goffard J-C, Grinsztejn B, Pozniak A, et al. Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1. AIDS 2007; 21:395-402. (Pubitemid 46263249)
35. Haubrich R, Berger D, Chiliade P, Colson A, Conant M, Gallant J, et al. Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients. AIDS 2007; 21:F11-F18. (Pubitemid 46568621)
36. Klein C, Chiu YL, Awni W, Zhu T, Heuser R, Doan T, et al. The tablet formulation of lopinavir/ritonavir provides similar bioavailability to the soft-gelatin capsule formulation with less pharmacokinetic variability and diminished food effect. J Acquir Immune Defic Syndr 2007; 44:401-410. (Pubitemid 46555374)
37. Hill A, Sawyer W, Gazzard B. Effects of first-line use of nucleoside analogues, efavirenz, and ritonavir-boosted protease inhibitors on lipid levels. HIV Clin Trials 2009; 10:1-12.